Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211406 · ClinicalTrials.gov registry record · Phase 1
Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)
A Phase 1 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00211406: Clinical Trial Phase 1 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
NCT00211406 is a Phase 1 study that was terminated before completion, run by Manhattan Eye, Ear & Throat Hospital. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211406, a Phase 1 study, was terminated before completion, sponsored by Manhattan Eye, Ear & Throat Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control diabetic retinopathy.
Interventions
- DRUG Anecortave Acetate Sterile Suspension (15 mg)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Why NCT00211406 stopped before completion
NCT00211406 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Anecortave Acetate Sterile Suspension (15 mg) is the first listed.
NCT00211406 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211406 about?
NCT00211406 is a clinical study titled "Treatment of Diabetic Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)". The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control diabetic retinopathy.
What is the current status of trial NCT00211406?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00211406?
The interventions under investigation include: Anecortave Acetate Sterile Suspension (15 mg) (DRUG).
Who is sponsoring clinical trial NCT00211406?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.